EMA approved a drug for patient use, prompting the National Centre for Pharmacoeconomics to demand price reduction and TDs to urge reimbursement.
3 reports, 2 independent
Updated Aug 25
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
EMA approved a drug for patient use, prompting the National Centre for Pharmacoeconomics to demand price reduction and TDs to urge reimbursement.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
-
HSE
homeshopping and e-commerce company and TV channel
-
National Centre for Pharmacoeconomics
organization in Dublin, Ireland
Nothing else this week.
Related events
- Alvotech submitted a regulatory application to the European Medicines Agency (EMA).
- Omeros Corporation's drug received FDA approval and is currently undergoing review by the European Medicines Agency.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- PolyPid Ltd's product received FDA Priority Review and gained single authorization across EU states from the EMA.